The U.S. Food and Drug Administration (FDA) has approved Lipfendra, a new medication for adults struggling to manage high LDL (low-density lipoprotein) cholesterol. It is the first PCSK9 inhibitor available as a daily pill, providing a significant alternative to existing treatments that require injections.
Lipfendra is designed to be used either alongside or instead of statins, the current standard of care. By blocking the PCSK9 protein, the drug helps the liver remove more cholesterol from the bloodstream. Clinical trials demonstrated that the medication can lower LDL cholesterol levels by approximately 56% to 59% in patients already taking maximum tolerated doses of statins.
Cardiologists have welcomed the development, noting that many patients avoid injectable cholesterol treatments due to discomfort or administrative hurdles. While existing injectable options like evolocumab and alirocumab have been available for years, Lipfendra offers a more convenient oral administration. The medication must be taken on an empty stomach.
The drug is expected to reach pharmacies within weeks, with a list price of approximately $10.50 per day, or $315 for a 30-day supply. Manufacturer Merck indicates that out-of-pocket costs will vary based on individual insurance coverage and that patient assistance programs are being established.
Clinical data currently validates the drug’s effectiveness in reducing LDL cholesterol levels; however, studies confirming its long-term impact on preventing heart attacks and strokes are still ongoing. Medical experts emphasize that diet, exercise, and lifestyle modifications remain the primary foundation for cardiovascular health.